191 related articles for article (PubMed ID: 3067007)
21. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
22. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
[No Abstract] [Full Text] [Related]
23. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
[No Abstract] [Full Text] [Related]
24. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
Chapuis B; Maurice P; Helg C; Wyss M; Jeannet M; Irlé C; Pipard G
Schweiz Med Wochenschr; 1986 Oct; 116(43):1475-6. PubMed ID: 3538379
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
26. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
27. T-cell depletion in allogeneic bone marrow transplantation for acute leukaemias.
Aversa F; Terenzi A; Carotti A; Velardi A; Latini P; Gambelunghe C; Grignani F; Martelli MF
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():69-72. PubMed ID: 2697440
[No Abstract] [Full Text] [Related]
28. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
Cobbold SP; Martin G; Qin S; Waldmann H
Nature; 1986 Sep 11-17; 323(6084):164-6. PubMed ID: 3528866
[TBL] [Abstract][Full Text] [Related]
30. Prevention of graft-versus-host disease by using immunotoxins.
Laurent G; Bouloux C
Prog Clin Biol Res; 1992; 377():129-36; discussion 137. PubMed ID: 1438408
[No Abstract] [Full Text] [Related]
31. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
[TBL] [Abstract][Full Text] [Related]
32. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo depletion of T cells.
Arnold R; Bunjes D; Wiesneth M; Hertenstein B; Theobald M; Heimpel H; Hale G; Waldmann H
Bone Marrow Transplant; 1993; 12 Suppl 3():S11-2. PubMed ID: 8124250
[TBL] [Abstract][Full Text] [Related]
34. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in patients with leukemia].
Löwenberg B; Sizoo W; Wagemaker G; Sintnicolaas K; Hendriks WD; Hagenbeek A
Ned Tijdschr Geneeskd; 1986 May; 130(19):872-6. PubMed ID: 3520349
[No Abstract] [Full Text] [Related]
35. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead.
Prentice HG; Brenner MK; Gottlieb D
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():225-8. PubMed ID: 2653508
[No Abstract] [Full Text] [Related]
36. [Prevention of graft versus host disease by in vitro immunodepletion of the graft].
Maraninchi D
Nouv Rev Fr Hematol (1978); 1985; 27(6):349-50. PubMed ID: 3912729
[No Abstract] [Full Text] [Related]
37. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.
Champlin R
Semin Hematol; 1992 Jul; 29(3 Suppl 2):46-52. PubMed ID: 1509294
[No Abstract] [Full Text] [Related]
38. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
40. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
